AU2012252151B2 - Anti-nerve growth factor antibodies and methods of preparing and using the same - Google Patents

Anti-nerve growth factor antibodies and methods of preparing and using the same Download PDF

Info

Publication number
AU2012252151B2
AU2012252151B2 AU2012252151A AU2012252151A AU2012252151B2 AU 2012252151 B2 AU2012252151 B2 AU 2012252151B2 AU 2012252151 A AU2012252151 A AU 2012252151A AU 2012252151 A AU2012252151 A AU 2012252151A AU 2012252151 B2 AU2012252151 B2 AU 2012252151B2
Authority
AU
Australia
Prior art keywords
amino acid
seq
antibody
acid sequence
canine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012252151A
Other languages
English (en)
Other versions
AU2012252151A1 (en
Inventor
David Gearing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44838842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012252151(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC
Publication of AU2012252151A1 publication Critical patent/AU2012252151A1/en
Assigned to NEXVET AUSTRALIA PTY LTD reassignment NEXVET AUSTRALIA PTY LTD Request for Assignment Assignors: NVIP PTY LTD
Application granted granted Critical
Publication of AU2012252151B2 publication Critical patent/AU2012252151B2/en
Assigned to ZOETIS SERVICES LLC reassignment ZOETIS SERVICES LLC Request for Assignment Assignors: NEXVET AUSTRALIA PTY LTD
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
AU2012252151A 2011-05-06 2012-05-08 Anti-nerve growth factor antibodies and methods of preparing and using the same Active AU2012252151B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161483481P 2011-05-06 2011-05-06
US61/483,481 2011-05-06
GBGB1114858.2A GB201114858D0 (en) 2011-08-29 2011-08-29 Anti-nerve growth factor antibodies and methods of using the same
GB1114858.2 2011-08-29
US201161531439P 2011-09-06 2011-09-06
US61/531,439 2011-09-06
PCT/GB2012/051002 WO2012153121A1 (en) 2011-05-06 2012-05-08 Anti-nerve growth factor antibodies and methods of preparing and using the same

Publications (2)

Publication Number Publication Date
AU2012252151A1 AU2012252151A1 (en) 2013-11-14
AU2012252151B2 true AU2012252151B2 (en) 2016-08-04

Family

ID=44838842

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012252151A Active AU2012252151B2 (en) 2011-05-06 2012-05-08 Anti-nerve growth factor antibodies and methods of preparing and using the same
AU2012252156A Active AU2012252156B2 (en) 2011-05-06 2012-05-08 Therapeutic canine immunoglobulins and methods of using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2012252156A Active AU2012252156B2 (en) 2011-05-06 2012-05-08 Therapeutic canine immunoglobulins and methods of using the same

Country Status (18)

Country Link
US (1) US10040849B2 (enExample)
EP (3) EP3502137A1 (enExample)
JP (2) JP5990701B2 (enExample)
KR (4) KR20160079939A (enExample)
CN (4) CN105833268A (enExample)
AU (2) AU2012252151B2 (enExample)
BR (2) BR112013028654A2 (enExample)
CA (3) CA2906505C (enExample)
DK (1) DK2705057T3 (enExample)
ES (2) ES2601400T3 (enExample)
GB (1) GB201114858D0 (enExample)
HU (1) HUE030654T2 (enExample)
MY (2) MY161724A (enExample)
PL (1) PL2705057T3 (enExample)
PT (1) PT2705057T (enExample)
RU (3) RU2627191C2 (enExample)
SG (5) SG10201607259TA (enExample)
WO (2) WO2012153126A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
SI2270048T1 (sl) 2002-12-24 2016-01-29 Rinat Neuroscience Corp. Protitelesa proti NGF-ju in postopki uporabe le-teh
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN113173993B (zh) 2013-12-20 2024-03-08 英特维特国际股份有限公司 拮抗性抗犬pd-1抗体
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
CA2961987A1 (en) 2014-09-30 2016-04-07 Intervet International B.V. Pd-l1 antibodies binding canine pd-l1
CN107683291B (zh) 2015-04-02 2021-11-19 英特维特国际股份有限公司 针对犬白介素-4受体α的抗体
US9758575B2 (en) * 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
UA123209C2 (uk) * 2015-05-22 2021-03-03 Астеллас Фарма Інк. Fab-ФРАГМЕНТ АНТИТІЛА ДО ЛЮДСЬКОГО NGF
KR20180057637A (ko) * 2015-08-31 2018-05-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개의 암을 치료하기 위한 키메라 aav-항-vegf
PT3390451T (pt) 2015-12-18 2025-03-12 Intervet Int Bv Anticorpos humanos caninizados para il-4r alfa humano e canino
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
JP6925981B2 (ja) 2016-01-06 2021-08-25 株式会社オーダーメードメディカルリサーチ Ｖｅｇｆとｎｒｐ１との結合を阻害する抗体
KR102293755B1 (ko) * 2016-01-06 2021-08-24 오더-메이드 메디컬 리서치 인코포레이티드 고친화성 항vegf 항체
WO2017142800A1 (en) * 2016-02-18 2017-08-24 Eli Lilly And Company Chimeric canine anti-cd20 antibody
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JP2021517461A (ja) 2018-03-12 2021-07-26 ゾエティス・サービシーズ・エルエルシー 抗ｎｇｆ抗体およびその方法
GB2578867A (en) * 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
JP7691365B2 (ja) * 2018-12-27 2025-06-11 エランコ・ユーエス・インコーポレイテッド 動物用ＩｇＧＦｃバリアント
AU2020312686A1 (en) 2019-07-15 2022-02-03 Intervet International B.V. Caninized antibodies against canine CTLA-4
US20230348577A1 (en) 2020-02-19 2023-11-02 Adivo Gmbh Modified fc regions
EP4114856A4 (en) * 2020-03-03 2023-11-22 Scout Bio, Inc. ANTIGEN BINDING MOLECULES AND THEIR USES
CA3198362A1 (en) * 2020-10-07 2022-04-14 Zoetis Services Llc Anti-ngf antibodies and methods of use thereof
TW202306990A (zh) 2021-05-12 2023-02-16 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｒａｎｋｌ和ｎｇｆ的抗原結合分子及其醫藥用途
IL311096A (en) 2021-08-31 2024-04-01 Scout Bio Inc Antigen binding molecules and their uses
EP4642795A2 (en) 2022-12-27 2025-11-05 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
KR20250151402A (ko) 2023-01-20 2025-10-21 인베티엑스 인코포레이티드 반려 동물에서 사용하기 위한 이중특이적 결합제
FR3148027A1 (fr) * 2023-04-24 2024-10-25 Peptinov Composition vaccinale anti-ngf

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060080A2 (en) * 2001-12-21 2003-07-24 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
WO2005061540A2 (en) * 2003-12-24 2005-07-07 Lay Line Genomics S.P.A. Method for the humanization of antibodies and humanized antibodies thereby obtained
WO2006131951A2 (en) * 2005-06-07 2006-12-14 Pangenetics B.V. MOLECULES THAT ARE ABLE TO INHIBIT THE BINDING BETWEEN NGF AND THE TrkA RECEPTOR AS ANALGESICS WITH PROLONGED EFFECT

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
JP2837240B2 (ja) * 1990-06-07 1998-12-14 財団法人化学及血清療法研究所 イヌ免疫グロブリンγ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
EP0590067A1 (en) 1991-06-14 1994-04-06 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
GB9202796D0 (en) 1992-02-11 1992-03-25 Wellcome Found Antiviral antibody
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU2001253282A1 (en) 2000-04-07 2001-10-23 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20030190705A1 (en) 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
PL379983A1 (pl) * 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Sposoby leczenia bólu polegające na podaniu antagonisty czynnika wzrostu nerwów i niesteroidowego leku przeciwzapalnego oraz zawierające je kompozycje
JP4263951B2 (ja) * 2003-06-20 2009-05-13 財団法人日本生物科学研究所 イヌ化抗体の作成方法および使用
JP2005104936A (ja) * 2003-10-01 2005-04-21 Nippon Zenyaku Kogyo Kk イヌｔａｒｃ抗体
JP2005143436A (ja) * 2003-11-18 2005-06-09 Nippon Zenyaku Kogyo Kk イヌｍｄｃ
PT1732949E (pt) * 2004-04-07 2010-03-23 Univ Minnesota Métodos de tratamento da dor associada ao cancro ósseo através da administração de um antagonista do factor de crescimento nervoso
US20060067930A1 (en) * 2004-08-19 2006-03-30 Genentech, Inc. Polypeptide variants with altered effector function
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US20070191272A1 (en) 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
EA201000053A1 (ru) * 2007-08-01 2010-08-30 Глаксо Груп Лимитед Новые антитела
US8722587B2 (en) * 2008-04-09 2014-05-13 The Trustees Of The University Of Pennsylvania Single chain fragment variable antibody libraries and uses thereof
US8337842B2 (en) 2008-09-04 2012-12-25 Vet Therapeutics, Inc. Monoclonal antibodies
EP2411050A4 (en) * 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
EP2413969A4 (en) 2009-03-30 2012-09-05 Boehringer Ingelheim Int FUSION PROTEINS WITH DOG FC ELEMENTS
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
EP2606067B1 (en) * 2010-08-19 2018-02-21 Zoetis Belgium S.A. Anti-ngf antibodies and their use
WO2012129330A1 (en) 2011-03-23 2012-09-27 Option Pharmaceutical, Llc Targeted cytokine for treatment of musculoskeletal diseases
EP3498732B1 (en) 2011-05-06 2021-11-17 Zoetis Services LLC Anti-nerve growth factor antibodies and methods of preparing and using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060080A2 (en) * 2001-12-21 2003-07-24 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
WO2005061540A2 (en) * 2003-12-24 2005-07-07 Lay Line Genomics S.P.A. Method for the humanization of antibodies and humanized antibodies thereby obtained
WO2006131951A2 (en) * 2005-06-07 2006-12-14 Pangenetics B.V. MOLECULES THAT ARE ABLE TO INHIBIT THE BINDING BETWEEN NGF AND THE TrkA RECEPTOR AS ANALGESICS WITH PROLONGED EFFECT

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COVACEUSZACH S, et al., J Mol. Biol., (2008), Vol 381, 881-896. *
PELAT T, et al., MABS, (2009), Vol 1, pp 377-381. *
WOLFGANG FR, et al., Drug Metabolism and Disposition, (1999), Vol 27 No 1, pp 21-25. *

Also Published As

Publication number Publication date
PT2705057T (pt) 2016-11-09
CA2835092C (en) 2020-12-08
CN103732620B (zh) 2017-02-22
NZ617446A (en) 2014-12-24
ES2601400T3 (es) 2017-02-15
CN103732622A (zh) 2014-04-16
JP2014522236A (ja) 2014-09-04
KR101637502B1 (ko) 2016-07-08
US10040849B2 (en) 2018-08-07
BR112013028523A2 (pt) 2016-11-29
BR112013028523A8 (pt) 2017-12-19
SG10201500954WA (en) 2015-04-29
KR101783398B1 (ko) 2017-10-10
CA2906505C (en) 2016-07-19
CN105999261A (zh) 2016-10-12
AU2012252156B2 (en) 2015-11-12
KR20170070271A (ko) 2017-06-21
KR20140056182A (ko) 2014-05-09
CA2835092A1 (en) 2012-11-15
KR20160079939A (ko) 2016-07-06
RU2626527C1 (ru) 2017-07-28
NZ617450A (en) 2015-01-30
RU2013154302A (ru) 2015-06-20
DK2705057T3 (en) 2016-11-28
KR20140041533A (ko) 2014-04-04
RU2013154304A (ru) 2015-06-20
CA2906505A1 (en) 2012-11-15
CA2834992C (en) 2016-07-26
SG10201500960TA (en) 2015-04-29
WO2012153126A1 (en) 2012-11-15
MY161295A (en) 2017-04-15
EP2705054A1 (en) 2014-03-12
SG194794A1 (en) 2013-12-30
SG10201607259TA (en) 2016-10-28
EP2705057B8 (en) 2016-09-21
GB201114858D0 (en) 2011-10-12
EP2705057B1 (en) 2016-08-03
CN105833268A (zh) 2016-08-10
US20150017154A1 (en) 2015-01-15
EP3502137A1 (en) 2019-06-26
HUE030654T2 (en) 2017-05-29
ES2704036T3 (es) 2019-03-13
JP5990701B2 (ja) 2016-09-14
JP2014516026A (ja) 2014-07-07
AU2012252151A1 (en) 2013-11-14
AU2012252156A1 (en) 2013-11-14
MY161724A (en) 2017-05-15
RU2644235C2 (ru) 2018-02-08
RU2627191C2 (ru) 2017-08-03
EP2705054B1 (en) 2018-11-14
SG194796A1 (en) 2013-12-30
BR112013028654A2 (pt) 2016-11-29
WO2012153121A1 (en) 2012-11-15
EP2705057A1 (en) 2014-03-12
CA2834992A1 (en) 2012-11-15
CN103732620A (zh) 2014-04-16
PL2705057T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
AU2012252151B2 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
JP6732990B2 (ja) 抗神経成長因子抗体並びに前記抗体の製造及び使用方法
AU2012252153B2 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
AU2012252152B2 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
CA2835094C (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
GB2528811A (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195571B (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195571A (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
NZ617446B2 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
EP4026845A1 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195781B (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195781A (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195570A (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195570B (en) Anti-nerve growth factor antibodies and methods of preparing and using the same

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NEXVET AUSTRALIA PTY LTD

Free format text: FORMER APPLICANT(S): NVIP PTY LTD

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ZOETIS SERVICES LLC

Free format text: FORMER OWNER(S): NEXVET AUSTRALIA PTY LTD